Alireza Sharafshah
Biographic Data
| ID | 7181367 |
|---|---|
| NAME | Alireza Sharafshah |
| GIVEN NAMES | Alireza |
| FAMILY NAME | Sharafshah |
| SIGNATURE | SHARAFSHAH A |
| AFFILIATIONS | Guilan University of Medical Sciences |
| ORCID | 0000-0001-8048-9587 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2017 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
The Emerging Crisis in Non-Prescribed Ketamine Use
BACKGROUND: Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. OBJECTIVE: This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines proposed mechanisms underlying its …
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Since 1990, substantial evidence from association studies has identified the D(2) dopamine receptor (DRD2) gene as a factor in the development of alcoholism [1][2][3][4]. The DRD2 gene has also been linked to other substance use disorders, including dependencies on cocaine, nicotine, and opioids, as well as obesity [5][6][7][8][9][10][11]. Dopamine in the brain, often referred to as the "stressrelief molecule," plays a central role in managing st…
Association of OPRD1 Gene Variants with Opioid Dependence in Addicted Male Individuals Undergoing Methadone Treatment in the North of Iran
Genetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease. Samples were selected among 202 opium-addicted participants undergoing methadone treatment and 202 healthy controls.…
No prominent works on this page.
Association of OPRD1 Gene Variants with Opioid Dependence in Addicted Male Individuals Undergoing Methadone Treatment in the North of Iran
Genetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease. Samples were selected among 202 opium-addicted participants undergoing methadone treatment and 202 healthy controls.…
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Since 1990, substantial evidence from association studies has identified the D(2) dopamine receptor (DRD2) gene as a factor in the development of alcoholism [1][2][3][4]. The DRD2 gene has also been linked to other substance use disorders, including dependencies on cocaine, nicotine, and opioids, as well as obesity [5][6][7][8][9][10][11]. Dopamine in the brain, often referred to as the "stressrelief molecule," plays a central role in managing st…
The Emerging Crisis in Non-Prescribed Ketamine Use
BACKGROUND: Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. OBJECTIVE: This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines proposed mechanisms underlying its …
Substance abuse (2 works) · Addiction (1 work) · Agonist (1 work) · Attention Deficit Hyperactivity Disorder (1 work) · Autism Spectrum Disorder Research (1 work) · Biology (1 work) · Cannabis and Cannabinoid Research (1 work) · Dopamine (1 work) · Dopamine receptor (1 work) · Dopamine receptor D2 (1 work)